London +4420 814 42225
Moscow +7495 543 9194
Kiev +38044 599 2950
info@mrcplast.com

Our Clients

Order Informer

 
Home > News >
 

Evonik expands lipids production to support Pfizer/BioNTech COVID-19 vaccine

February 12/2021

MOSCOW (MRC) -- Evonik Industries says it is expanding its partnership with BioNTech (Mainz, Germany) to increase supply security for the Pfizer-BioNTech COVID-19 vaccine and is investing in a short-term production expansion for specialty lipids, essential for messenger ribonucleic acid (mRNA) COVID-19 vaccines, reported Chemweek.

The company says that "commercial lipid quantities" are to be produced at Evoniks Hanau and Dossenheim, Germany, sites as early as the second half of 2021. Further details have not been disclosed.

"The pandemic requires decisive action," says Christian Kullmann, chairman of Evonik. "We are therefore doing everything possible to supply our partners with the critical lipids they need. At the same time, we are expanding our production capacity and competencies along the entire value chain."

Lipids are fundamental to produce mRNA-based vaccines and only with an increase in lipid supply can the volume of vaccine be increased, Evonik notes. In mRNA-based vaccines, the mRNA is enclosed in a lipid nanoparticle (LNP) that is comprised of specific lipids, it says. The LNP protects the mRNA and delivers it safely into the cell, where it is released so that the vaccine can exert its effect, the company says.

It follows a similar announcement by Merck KGaA, which is expanding its partnership with BioNTech to accelerate the supply of lipids and increase the amount of lipid delivery toward the end of 2021.

As MRC informed earlier, in February, 2020, Dow and Evonik entered into an exclusive technology partnership. Together, they plan to bring a unique method for directly synthesizing propylene glycol (PG) from propylene and hydrogen peroxide to market maturity.

Propylene is the main feedstock for the production of polypropylene (PP).

According to MRC's ScanPlast report, PP shipments to the Russian market reached 1 240,000 tonnes in 2020 (calculated using the formula: production, minus exports, plus imports, exluding producers' inventories as of 1 January, 2020).

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evoniks corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees.


mrcplast.com
Author:Margaret Volkova
Tags:PP, propylene, medicine, petrochemistry, adhesives, Dow, Evonik, Merck, Germany, Russia, USA.
Category:General News
|
| More

Leave a comment

MRC help

 


 All News   News subscribe